The management of multiple sclerosis in children: a European view

Angelo Ghezzi; Brenda Banwell; Alexey Boyko; Maria Pia Amato; Banu Anlar; Morten Blinkenberg; Maartje Boon; Massimo Filippi; Sergiusz Jozwiak; Immy Ketelslegers; Barbara Kornek; Ming Lim; Eva Lindstrom; Congor Nadj; Rinze Neuteboom; Maria A Rocca; Kevin Rostasy; Marc Tardieu; Evangeline Wassmer; Coriene Catsman-Berrevoets; Rogier Hintzen

doi:10.1177/1352458510375568

The management of multiple sclerosis in children: a European view

Angelo Ghezzi, Brenda Banwell, Alexey Boyko, Maria Pia Amato, Banu Anlar, Morten Blinkenberg, Maartje Boon, Massimo Filippi, Sergiusz Jozwiak, Immy Ketelslegers, Barbara Kornek, Ming Lim, Eva Lindstrom, Congor Nadj, Rinze Neuteboom, Maria A Rocca, Kevin Rostasy, Marc Tardieu, Evangeline Wassmer, Coriene Catsman-BerrevoetsRogier Hintzen

Institut for Klinisk Medicin

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

97 Citationer (Scopus)

Abstract

About 3-5% of all patients with multiple sclerosis experience the onset of their disease under the age of 16. A significant proportion of paediatric multiple sclerosis patients develop significant cognitive disturbances and persistent physical disability. The high relapse rate and the morbidity in the paediatric multiple sclerosis population has triggered the use of disease-modifying therapies that have been shown to reduce relapse rate, disease progression and cognitive decline in adult patients with multiple sclerosis. Hard evidence for the right treatment and its appropriate timing is scarce in paediatric multiple sclerosis. Nevertheless, expertise in this field has grown thanks to recent open-label trials and experience generated in specialized centres. In spring 2009, a first meeting was held in Rotterdam with clinicians from 11 European countries (one from Canada) that are all active in the management of paediatric multiple sclerosis. One of the aims was to generate a common view on the management of paediatric multiple sclerosis patients. The result of this meeting is presented here to help standardize treatment and to support clinicians with less experience in this field.

Originalsprog	Engelsk
Tidsskrift	Multiple Sclerosis
Vol/bind	16
Udgave nummer	10
Sider (fra-til)	1258-67
Antal sider	10
ISSN	1352-4585
DOI	https://doi.org/10.1177/1352458510375568
Status	Udgivet - 1 okt. 2010

Adgang til dokumentet

10.1177/1352458510375568

Citationsformater

Ghezzi, A., Banwell, B., Boyko, A., Amato, M. P., Anlar, B., Blinkenberg, M., Boon, M., Filippi, M., Jozwiak, S., Ketelslegers, I., Kornek, B., Lim, M., Lindstrom, E., Nadj, C., Neuteboom, R., Rocca, M. A., Rostasy, K., Tardieu, M., Wassmer, E., ... Hintzen, R. (2010). The management of multiple sclerosis in children: a European view. Multiple Sclerosis, 16(10), 1258-67. https://doi.org/10.1177/1352458510375568

Ghezzi, A, Banwell, B, Boyko, A, Amato, MP, Anlar, B, Blinkenberg, M, Boon, M, Filippi, M, Jozwiak, S, Ketelslegers, I, Kornek, B, Lim, M, Lindstrom, E, Nadj, C, Neuteboom, R, Rocca, MA, Rostasy, K, Tardieu, M, Wassmer, E, Catsman-Berrevoets, C & Hintzen, R 2010, 'The management of multiple sclerosis in children: a European view', Multiple Sclerosis, bind 16, nr. 10, s. 1258-67. https://doi.org/10.1177/1352458510375568

@article{ec7706105000408b8c9d21e369ba40fb,

title = "The management of multiple sclerosis in children: a European view",

abstract = "About 3-5% of all patients with multiple sclerosis experience the onset of their disease under the age of 16. A significant proportion of paediatric multiple sclerosis patients develop significant cognitive disturbances and persistent physical disability. The high relapse rate and the morbidity in the paediatric multiple sclerosis population has triggered the use of disease-modifying therapies that have been shown to reduce relapse rate, disease progression and cognitive decline in adult patients with multiple sclerosis. Hard evidence for the right treatment and its appropriate timing is scarce in paediatric multiple sclerosis. Nevertheless, expertise in this field has grown thanks to recent open-label trials and experience generated in specialized centres. In spring 2009, a first meeting was held in Rotterdam with clinicians from 11 European countries (one from Canada) that are all active in the management of paediatric multiple sclerosis. One of the aims was to generate a common view on the management of paediatric multiple sclerosis patients. The result of this meeting is presented here to help standardize treatment and to support clinicians with less experience in this field.",

author = "Angelo Ghezzi and Brenda Banwell and Alexey Boyko and Amato, {Maria Pia} and Banu Anlar and Morten Blinkenberg and Maartje Boon and Massimo Filippi and Sergiusz Jozwiak and Immy Ketelslegers and Barbara Kornek and Ming Lim and Eva Lindstrom and Congor Nadj and Rinze Neuteboom and Rocca, {Maria A} and Kevin Rostasy and Marc Tardieu and Evangeline Wassmer and Coriene Catsman-Berrevoets and Rogier Hintzen",

year = "2010",

month = oct,

day = "1",

doi = "10.1177/1352458510375568",

language = "English",

volume = "16",

pages = "1258--67",

journal = "Multiple Sclerosis",

issn = "1352-4585",

publisher = "SAGE Publications",

number = "10",

}

TY - JOUR

T1 - The management of multiple sclerosis in children: a European view

AU - Ghezzi, Angelo

AU - Banwell, Brenda

AU - Boyko, Alexey

AU - Amato, Maria Pia

AU - Anlar, Banu

AU - Blinkenberg, Morten

AU - Boon, Maartje

AU - Filippi, Massimo

AU - Jozwiak, Sergiusz

AU - Ketelslegers, Immy

AU - Kornek, Barbara

AU - Lim, Ming

AU - Lindstrom, Eva

AU - Nadj, Congor

AU - Neuteboom, Rinze

AU - Rocca, Maria A

AU - Rostasy, Kevin

AU - Tardieu, Marc

AU - Wassmer, Evangeline

AU - Catsman-Berrevoets, Coriene

AU - Hintzen, Rogier

PY - 2010/10/1

Y1 - 2010/10/1

N2 - About 3-5% of all patients with multiple sclerosis experience the onset of their disease under the age of 16. A significant proportion of paediatric multiple sclerosis patients develop significant cognitive disturbances and persistent physical disability. The high relapse rate and the morbidity in the paediatric multiple sclerosis population has triggered the use of disease-modifying therapies that have been shown to reduce relapse rate, disease progression and cognitive decline in adult patients with multiple sclerosis. Hard evidence for the right treatment and its appropriate timing is scarce in paediatric multiple sclerosis. Nevertheless, expertise in this field has grown thanks to recent open-label trials and experience generated in specialized centres. In spring 2009, a first meeting was held in Rotterdam with clinicians from 11 European countries (one from Canada) that are all active in the management of paediatric multiple sclerosis. One of the aims was to generate a common view on the management of paediatric multiple sclerosis patients. The result of this meeting is presented here to help standardize treatment and to support clinicians with less experience in this field.

AB - About 3-5% of all patients with multiple sclerosis experience the onset of their disease under the age of 16. A significant proportion of paediatric multiple sclerosis patients develop significant cognitive disturbances and persistent physical disability. The high relapse rate and the morbidity in the paediatric multiple sclerosis population has triggered the use of disease-modifying therapies that have been shown to reduce relapse rate, disease progression and cognitive decline in adult patients with multiple sclerosis. Hard evidence for the right treatment and its appropriate timing is scarce in paediatric multiple sclerosis. Nevertheless, expertise in this field has grown thanks to recent open-label trials and experience generated in specialized centres. In spring 2009, a first meeting was held in Rotterdam with clinicians from 11 European countries (one from Canada) that are all active in the management of paediatric multiple sclerosis. One of the aims was to generate a common view on the management of paediatric multiple sclerosis patients. The result of this meeting is presented here to help standardize treatment and to support clinicians with less experience in this field.

U2 - 10.1177/1352458510375568

DO - 10.1177/1352458510375568

M3 - Journal article

SN - 1352-4585

VL - 16

SP - 1258

EP - 1267

JO - Multiple Sclerosis

JF - Multiple Sclerosis

IS - 10

ER -